Abedalrahman Maen Addassi: Edoxaban’s Journey Shows How Targeted Pharmacology and Real-World Data Converge
Abedalrahman Maen Addassi, Pharmacist, shared a post on LinkedIn:
”Innovation in Anticoagulation: Edoxaban by Daiichi Sankyo
In a world where stroke prevention and venous thromboembolism management are critical, Edoxaban (Savaysa) stands out as a once-daily oral anticoagulant that’s reshaping clinical practice.
- FDA Approval Date: January 8, 2015 A B
- Mechanism of Action: Edoxaban is a direct Factor Xa inhibitor, selectively blocking a key step in the coagulation cascade to prevent thrombus formation C.
Indications:
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following initial parenteral anticoagulation A B
Side Effects:
- Most common: bleeding, including gastrointestinal and intracranial hemorrhage
- Others: anemia, rash, liver enzyme elevation—requiring careful renal function monitoring, especially in patients with CrCL >95 mL/min B
How Does It Compare?
- Warfarin: Edoxaban showed non-inferior efficacy with lower rates of major bleeding in ENGAGE AF-TIMI 48 trial B
- Rivaroxaban and Apixaban: All are Factor Xa inhibitors, but edoxaban offers once-daily dosing and a favorable bleeding profile in select populations
- Dabigatran: A direct thrombin inhibitor—different mechanism, twice-daily dosing, and higher GI bleeding risk
Backed by global trials like ENGAGE AF-TIMI 48 and Hokusai-VTE, edoxaban continues to expand its footprint across more than 40 countries C.
As a recent pharmacy graduate passionate about medical information and therapeutic innovation, I find edoxaban’s journey a powerful example of how targeted pharmacology and real-world data can converge to improve patient outcomes.
Let’s connect if you’re working in anticoagulation, clinical trials, or medical affairs—I’d love to exchange insights!”
Stay updated with Hemostasis Today.
-
Apr 22, 2026, 17:19Ralf Ludwig: Bridging Population Data and Immunology in Inflammatory Diseases
-
Apr 22, 2026, 17:15Giacomo Rossi: Genetic Study Reveals 10 Genes in Hyperemesis Gravidarum
-
Apr 22, 2026, 17:06Maura Boerio: Quantifying Barriers to Care in Vascular Ehlers-Danlos Syndrome
-
Apr 22, 2026, 17:05Kausik Ray։ Metabolically Healthy Obesity Is Being Re-Evaluated as a High-Risk Condition Needing Closer Attention
-
Apr 22, 2026, 16:58Baba-Jallah Epega: Sickle Cell Resilience Through Patient Voices and Clinical Insight
-
Apr 22, 2026, 16:44Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
-
Apr 22, 2026, 16:29CBTH 2026 Opens with First Workshop in Germany – European Hematology Association
-
Apr 22, 2026, 16:16Christopher Pittman: Superficial Venous Disease Needs Arterial-Level Follow-Up
-
Apr 22, 2026, 15:47Mohammed Alo: Being Fit Does Not Protect You from High LDL